Session: SAT 554-583-Male Reproductive Endocrinology & Case Reports
Poster Board SAT-583
Henrik H. Thomsen1, Holger J. Møller2, Christian Trolle1, Kristian A. Groth3, Anne Skakkebæk1, Anders Bojesen4, Christian Høst1, Claus H. Gravholt1,3
1Department of Endocrinology and Internal Medicine and Medical Research Laboratories, Clinical Institute, Aarhus University Hospital, Aarhus C, Denmark
2Department of Clinical Biochemistry, Aarhus University Hospital, Denmark
3Department of Molecular Medicine, Aarhus University Hospital, Denmark
4Department of Clinical Genetics, Vejle Hospital, Sygehus Lillebaelt, Vejle, Denmark
Background: Soluble CD163 (sCD163) is a novel and promising marker linked to states of low grade inflammation such as diabetes, obesity, liver disease and atherosclerosis. This study aimed to assess the levels of sCD163 in Turner and Klinefelter Syndromes. Secondly the level of sCD163 in regards to treatment with sex hormone therapy in males with and without Klinefelter Syndrome and females with and without Turner Syndrome respectively.
Design: Case-control study and placebo-controlled randomized studies.
Materials and Methods: Males with Klinefelter Syndrome (n=70) and age-matched controls (n=71) participating in a cross-sectional study, 13 healthy males from an experimental hypogonadism study. Females with Turner Syndrome (n=8) and healthy age matched female controls (n=8) participating in a randomized cross over trial along with 92 females with Turner Syndrome and 68 healthy age matched female controls from a cross sectional study. All subjects were recruited through our outpatient clinic or through advertisement.
Outcome measures: sCD163, sex hormones, CRP, markers of insulin sensitivity, and body composition.
Results: Males with Klinefelter Syndrome had higher levels of sCD163 compared with controls (1.41±0.39 vs. 2.06±0.99, p<0.001) and the levels correlated to testosterone (r -0.306, p=0.01), BMI (r -0.360, p<0.001) and HOMA IR (r 0.456, p<0.001). Females with Turner Syndrome not receiving hormone replacement therapy had higher levels of sCD163 (1.38±0.44 vs. 0.91±0.40, p=0.04). Hormone replacement therapy and oral contraceptive treatment decreased sCD163 in Turner Syndrome (1.07±0.30) and controls (0.55±0.36), respectively, with significance in both groups (p=0.01 and p=0.04).
Conclusion: Levels of sCD163 are influenced by both endogenous and exogenous sex hormones in Klinefelter and Turner Syndromes.
Nothing to Disclose: HHT, HJM, CT, KAG, AS, AB, CH, CHG
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters